 |
인쇄하기
취소
|
Cervarix, GSK's cervical cancer vaccine, approved in Korea
GlaxoSmithKline (GSK) says that the Korea Food and Drug Administration has granted a marketing authorization for its cervical cancer vaccine, Cervarix.
Cervarix, with its innovative AS04 adjuvant system, is indicated for the prevention of precancerous cervical lesions and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18. The indication is based on data generate...
Cervarix, with its innovative AS04 adjuvant system, is indicated for the prevention of precancerous cervical lesions and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18. The indication is based on data generate...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.